X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6374) 6374
Book Review (864) 864
Publication (256) 256
Newspaper Article (26) 26
Conference Proceeding (22) 22
Newsletter (16) 16
Magazine Article (12) 12
Book Chapter (5) 5
Dissertation (2) 2
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5892) 5892
humans (5603) 5603
female (3501) 3501
male (3175) 3175
melphalan - therapeutic use (2792) 2792
middle aged (2786) 2786
melphalan - administration & dosage (2238) 2238
antineoplastic combined chemotherapy protocols - therapeutic use (2229) 2229
adult (2132) 2132
aged (2092) 2092
oncology (2035) 2035
melphalan (1875) 1875
hematology (1681) 1681
multiple myeloma - drug therapy (1671) 1671
treatment outcome (1191) 1191
chemotherapy (1187) 1187
multiple myeloma (1034) 1034
combined modality therapy (1021) 1021
transplantation (972) 972
animals (848) 848
transplantation, autologous (798) 798
prognosis (779) 779
abridged index medicus (755) 755
antineoplastic agents - therapeutic use (747) 747
stem-cell transplantation (736) 736
cancer (712) 712
multiple myeloma - therapy (709) 709
cyclophosphamide - administration & dosage (703) 703
therapy (658) 658
melphalan - adverse effects (599) 599
bortezomib (597) 597
cyclophosphamide - therapeutic use (589) 589
hematopoietic stem cell transplantation (572) 572
antineoplastic combined chemotherapy protocols - adverse effects (570) 570
survival (560) 560
retrospective studies (550) 550
adolescent (544) 544
immunology (544) 544
mice (539) 539
prednisone - administration & dosage (536) 536
multiple myeloma - mortality (531) 531
survival analysis (530) 530
follow-up studies (524) 524
aged, 80 and over (517) 517
disease-free survival (511) 511
time factors (508) 508
care and treatment (487) 487
survival rate (487) 487
vincristine - administration & dosage (485) 485
remission induction (477) 477
stem cells (477) 477
antineoplastic agents, alkylating - therapeutic use (472) 472
drug therapy, combination (471) 471
prednisone - therapeutic use (456) 456
doxorubicin - administration & dosage (451) 451
antineoplastic combined chemotherapy protocols - administration & dosage (442) 442
dexamethasone - administration & dosage (429) 429
dexamethasone (423) 423
stem cell transplantation (418) 418
high-dose melphalan (411) 411
multiple myeloma - pathology (408) 408
dose-response relationship, drug (390) 390
cyclophosphamide (379) 379
child (378) 378
bone marrow transplantation (368) 368
thalidomide (361) 361
prednisone (359) 359
etoposide - administration & dosage (355) 355
neoplasm staging (346) 346
bone-marrow transplantation (345) 345
multiple myeloma - complications (345) 345
carmustine - administration & dosage (342) 342
recurrence (338) 338
multiple-myeloma (336) 336
melanoma - drug therapy (332) 332
surgery (328) 328
medicine, general & internal (319) 319
child, preschool (314) 314
bone-marrow-transplantation (308) 308
transplantation conditioning - methods (304) 304
antineoplastic agents, alkylating - administration & dosage (303) 303
medicine & public health (299) 299
multiple myeloma - diagnosis (298) 298
drug administration schedule (290) 290
hematopoietic stem cell transplantation - methods (290) 290
antineoplastic agents - administration & dosage (289) 289
melphalan - pharmacology (285) 285
prospective studies (283) 283
trial (280) 280
analysis (279) 279
clinical trials as topic (274) 274
cytarabine - administration & dosage (272) 272
health aspects (268) 268
thalidomide - administration & dosage (265) 265
pharmacology & pharmacy (261) 261
chemotherapy, cancer, regional perfusion (250) 250
high-dose chemotherapy (246) 246
infant (245) 245
research (242) 242
hematology, oncology and palliative medicine (240) 240
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5652) 5652
Russian (167) 167
German (153) 153
French (129) 129
Japanese (114) 114
Spanish (61) 61
Italian (49) 49
Polish (28) 28
Chinese (23) 23
Czech (11) 11
Dutch (9) 9
Hebrew (8) 8
Hungarian (6) 6
Norwegian (5) 5
Swedish (5) 5
Danish (3) 3
Slovak (3) 3
Bulgarian (2) 2
Croatian (2) 2
Finnish (2) 2
Serbian (2) 2
Portuguese (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Hematology, ISSN 0361-8609, 11/2015, Volume 90, Issue 11, pp. 981 - 985
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1617 - 1629
Summary Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | ONCOLOGY | CONSOLIDATION THERAPY | INITIAL TREATMENT | THALIDOMIDE | BORTEZOMIB | INDUCTION | STEM-CELL TRANSPLANTATION | DEXAMETHASONE COMBINATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Cyclophosphamide - therapeutic use | Thalidomide - analogs & derivatives | Multiple Myeloma - therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Thalidomide - adverse effects | Prednisone - adverse effects | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease Progression | Disease-Free Survival | Czech Republic | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Thalidomide - therapeutic use | Australia | Prednisone - therapeutic use | Medical colleges | Cyclophosphamide | Care and treatment | Chemotherapy | Dexamethasone | Multiple myeloma | Stem cells | Product development | Prednisone | Transplantation | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2012, Volume 30, Issue 24, pp. 2946 - 2955
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 986 - 993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label,... 
LOW-DOSE WARFARIN | DEXAMETHASONE | THERAPY | VENOUS THROMBOEMBOLISM | ONCOLOGY | DEEP-VEIN THROMBOSIS | PREDNISONE PLUS THALIDOMIDE | BORTEZOMIB | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | MELPHALAN | Multiple Myeloma - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Warfarin - adverse effects | Male | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Time Factors | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Cardiovascular Diseases - mortality | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Risk Assessment | Multiple Myeloma - complications | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Italy | Aged | Hemorrhage - chemically induced | Index Medicus
Journal Article
Journal Article
Blood, ISSN 0006-4971, 2011, Volume 118, Issue 9, pp. 2413 - 2419
To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated... 
CRITERIA | DEXAMETHASONE | AGENTS | HEMATOLOGY | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Prospective Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Feasibility Studies | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Hematopoietic Stem Cell Mobilization | Transplantation Conditioning - methods | Mycophenolic Acid - administration & dosage | Graft vs Host Disease - etiology | Multiple Myeloma - surgery | Immunosuppressive Agents - administration & dosage | Thalidomide - adverse effects | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Acute Disease | Immunologic Factors - administration & dosage | Combined Modality Therapy | Thalidomide - administration & dosage | Remission Induction | Cyclosporine - therapeutic use | Disease-Free Survival | Melphalan - administration & dosage | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Cyclosporine - administration & dosage | Lymphocyte Count | Aged | Immunologic Factors - adverse effects | Hematopoietic Stem Cell Transplantation - methods | Thalidomide - therapeutic use | Immunologic Factors - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 2011, Volume 22, Issue 5, pp. 1221 - 1227
Journal Article
Haematologica, ISSN 0390-6078, 2017, Volume 102, Issue 2, pp. 356 - 363
Journal Article
Cancer Science, ISSN 1347-9032, 09/2018, Volume 109, Issue 9, pp. 2830 - 2840
Although induction immunochemotherapy including high‐dose cytarabine and rituximab followed by high‐dose chemotherapy ( HDC ) with autologous stem cell... 
cytarabine | high‐dose chemotherapy | mantle cell lymphoma | rituximab | autologous stem cell transplantation | high-dose chemotherapy | ONCOLOGY-GROUP | PROSPECTIVE RANDOMIZED-TRIAL | MALIGNANT-LYMPHOMA | PROGRESSION-FREE SURVIVAL | PHASE-II | HIGH-DOSE CYTARABINE | THERAPY | ONCOLOGY | INDOLENT LYMPHOMA | NON-HODGKINS-LYMPHOMA | Doxorubicin - therapeutic use | Immunotherapy - methods | Cytarabine - therapeutic use | Humans | Middle Aged | Lymphoma, Mantle-Cell - pathology | Male | Transplantation, Autologous | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Young Adult | Rituximab - therapeutic use | Adult | Female | Antigens, Neoplasm - analysis | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Disease-Free Survival | Dexamethasone - therapeutic use | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Aged | Prednisone - therapeutic use | Development and progression | Chemotherapy | Lymphomas | Transplantation | Stem cells | Cancer | Autografts | Research funding | Toxicity | Stem cell transplantation | Rituximab | Lymphoma | Hematopoietic stem cells | Hepatitis | Cytarabine | Medical prognosis | Mantle cell lymphoma | Peripheral blood | Pharmaceuticals | Index Medicus | Original
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 6, pp. 1046 - 1053
Abstract There are limited data to guide the choice of high-dose therapy (HDT) regimen before autologous hematopoietic cell transplantation (AHCT) for patients... 
Hematology, Oncology and Palliative Medicine | Idiopathic pneumonia syndrome | Autologous transplantation | Lymphoma | RISK-FACTORS | PROGNOSTIC-FACTORS | SPANISH COOPERATIVE GROUP | CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | Idiopathic pneumonia | PREPARATIVE REGIMENS | IMMUNOLOGY | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | syndrome | DISEASE | NON-HODGKINS-LYMPHOMA | HEMATOLOGY | Myeloablative Agonists - therapeutic use | Lymphoma, Non-Hodgkin - immunology | Whole-Body Irradiation | Cytarabine - therapeutic use | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Transplantation, Autologous | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Carmustine - therapeutic use | Aged, 80 and over | Hodgkin Disease - mortality | Adult | Female | Registries | Retrospective Studies | Transplantation Conditioning - methods | Busulfan - therapeutic use | Drug Administration Schedule | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Adolescent | Survival Analysis | Hodgkin Disease - immunology | Aged | Lymphoma, Non-Hodgkin - mortality | Care and treatment | Patient outcomes | Analysis | Mortality | Lymphomas | Transplantation | Hematopoietic stem cells | Index Medicus | idiopathic pneumonia syndrome | autologous transplant | lymphoma
Journal Article
Blood, ISSN 0006-4971, 01/2016, Volume 127, Issue 4, pp. 420 - 425
Journal Article